Back

Efficient delivery of gene editors using intein-engineered virus-like particles

Zhou, G.; Hou, V. W. Q.; Zhou, H.; Roudi, S.; Suermondt, J.; Gustafsson, O.; Niu, Z.; MAMAND, D. R. A.; Van Hoecke, L.; Wiklander, O. P. B.; Vandenbroucke, R. E.; Nordin, J. Z.; Gorgens, A.; EL Andaloussi, S.; Liang, X.

2026-01-26 molecular biology
10.64898/2026.01.25.701600 bioRxiv
Show abstract

Virus-like particles (VLPs) represent a promising next-generation drug delivery platform. However, conventional VLPs rely on multiple viral components for effective cargo encapsulation and delivery, raising safety concerns. Here, we present a novel strategy to engineer immature VLPs using a self-cleaving intein system. We employed viral Gag proteins as sorting domains, linking cargo proteins to Gag through inteins, thereby eliminating the need for the conventional protease cleavage typically mediated by the gag-pol protein. During VLP biogenesis, intein-mediated cleavage released cargo proteins into the lumen, enabling efficient intracellular delivery when VLP surfaces are pseudotyped with VSV-G. Optimal candidates for delivering Cre recombinase and gene editing tools (Cas9, Cas12a and base editors) were identified by screening various Gag proteins. Notably, these VLPs achieved robust gene editing in primary cells, including naive and activated T cells, as well as hematopoietic stem and progenitor cells (HSPCs). A single local intracerebroventricular (ICV) infusion of optimized particles induced up to 60% tdTomato expression in the brain regions of reporter mice, while intravenous injection resulted in significant recombination (up to 70%) of a variety of cell types across organs. Collectively, we developed a simplified, efficient VLP platform for intracellular cargo delivery with broad therapeutic potential for gene editing and treatment of human diseases.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Advanced Materials
53 papers in training set
Top 0.2%
12.3%
2
Advanced Science
249 papers in training set
Top 1%
10.4%
3
Nature Communications
4913 papers in training set
Top 21%
9.1%
4
Molecular Therapy
71 papers in training set
Top 0.3%
6.8%
5
Nature Biotechnology
147 papers in training set
Top 1%
6.4%
6
Protein & Cell
25 papers in training set
Top 0.3%
6.3%
50% of probability mass above
7
Journal of Controlled Release
39 papers in training set
Top 0.2%
4.8%
8
Cell Discovery
54 papers in training set
Top 1%
3.6%
9
ACS Central Science
66 papers in training set
Top 0.5%
3.1%
10
ACS Nano
99 papers in training set
Top 2%
2.4%
11
Journal of the American Chemical Society
199 papers in training set
Top 3%
2.1%
12
Angewandte Chemie International Edition
81 papers in training set
Top 2%
2.1%
13
Nucleic Acids Research
1128 papers in training set
Top 10%
1.8%
14
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.2%
1.7%
15
Bioconjugate Chemistry
17 papers in training set
Top 0.1%
1.7%
16
Science Advances
1098 papers in training set
Top 21%
1.3%
17
Cell Reports Medicine
140 papers in training set
Top 5%
1.3%
18
Angewandte Chemie
12 papers in training set
Top 0.2%
0.9%
19
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.6%
0.9%
20
The Lancet Infectious Diseases
71 papers in training set
Top 2%
0.9%
21
ACS Synthetic Biology
256 papers in training set
Top 2%
0.9%
22
ACS Chemical Biology
150 papers in training set
Top 2%
0.8%
23
Cell Reports Methods
141 papers in training set
Top 5%
0.7%
24
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 44%
0.7%
25
International Journal of Biological Macromolecules
65 papers in training set
Top 4%
0.7%
26
Cell Reports Physical Science
18 papers in training set
Top 1%
0.6%
27
Cell Stem Cell
57 papers in training set
Top 3%
0.6%
28
Small
70 papers in training set
Top 1%
0.6%